Does Strattera Cause Sleepiness and Nausea in ADHD Patients?
Yes, Strattera (atomoxetine) commonly causes both somnolence (sleepiness) and nausea in patients with ADHD, with these being among the most frequently reported adverse effects in clinical trials.
Evidence from FDA Drug Label and Clinical Trials
The FDA-approved prescribing information clearly identifies both somnolence and nausea as common adverse reactions 1. In acute placebo-controlled trials in children and adolescents:
- Nausea occurred in 10% of atomoxetine-treated patients vs. 5% on placebo
- Somnolence occurred in 11% of atomoxetine-treated patients vs. 4% on placebo 1
These adverse effects were among the most commonly observed reactions with incidence ≥5% and at least twice the placebo rate 1.
Clinical Significance and Management
Somnolence (Sleepiness):
- Somnolence was reported as a reason for discontinuation in 0.3% of patients 1
- This side effect can actually be leveraged therapeutically—evening dosing is preferable when somnolence occurs, allowing the sedating effect to aid with sleep rather than interfere with daytime functioning 2
- Atomoxetine appears "sleep neutral" overall and does not exacerbate sleep disturbances like stimulants can 3
Nausea:
- Nausea occurred in 10% of pediatric patients and was a reason for discontinuation in 0.2% 1
- This adverse effect is generally mild to moderate and transient 4, 5
- Splitting the daily dose into two equal portions (morning and evening) can reduce gastrointestinal side effects including nausea 2
Important Metabolizer Considerations
Poor CYP2D6 metabolizers (approximately 7% of the population) experience significantly higher rates of adverse effects including nausea and somnolence due to elevated plasma levels and prolonged half-life 2, 4. The discontinuation rate was nearly double in poor metabolizers (11.2%) compared to extensive metabolizers (6.3%) 1.
Comparative Context
While nausea and somnolence are common with atomoxetine, the adverse effect profile differs from stimulants. Somnolence is MORE common with atomoxetine, while insomnia is MORE common with stimulants 4. This makes atomoxetine particularly useful when sleep disturbance is already a concern.
Practical Clinical Approach
When prescribing atomoxetine:
- Warn patients upfront that nausea and sleepiness are common, especially during initial titration
- Consider evening-only dosing if somnolence is problematic during the day
- Split dosing (BID) if gastrointestinal symptoms like nausea are bothersome
- Reassure patients that these effects are typically mild-to-moderate and often resolve with continued treatment 4, 5
- Monitor more closely if the patient is known to be a poor CYP2D6 metabolizer or is taking CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine) 1
The overall tolerability remains favorable, with only 3.0% of pediatric patients discontinuing due to adverse reactions in controlled trials 1.